Prospective Observational Study on Stelara Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PROSE
- Sponsors Janssen-Cilag
- 24 Jan 2019 Planned End Date changed from 30 Apr 2021 to 21 Nov 2021.
- 24 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated